Anticancer activity of isomers of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole.
Three phenylimidazothiazole isomers, L-(-)-form (levamisole), D-(+)-form (dexamisole), and DL-(+/-)-form (tetramisole), modulate mouse and rat immune responsiveness. They depress the relapse of urinary bladder cancer, BC-47, when they are used with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for treatment of rats bearing BC-47. Levamisole was the most effective isomer. Effectiveness of the isomers is expressed by their ability to enhance the number of plaque-forming cells to sheep red blood cells. They also stimulate the DNA synthesis of murine lymphocytes in vitro.
D000818:Animals; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology; D009602:Nitrosamines; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D051381:Rats; D013237:Stereoisomerism; D013773:Tetramisole / Q000008:administration & dosage / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology
D009602:Nitrosamines; D009607:Nitrosourea Compounds; D007978:Levamisole; D013773:Tetramisole